New approaches to the pharmacotherapy of neuropathic pain

Expert Review of Clinical Pharmacology

Volumn 1, Issue 5, 2008, Pages 683-693

  Besson, Marie ^a   Piguet, Valérie ^a   Dayer, Pierre ^a   Desmeules, Jules ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Clinical mechanism based approach; Evidence based approach; Fundamental mechanism based approach; Neuropathic pain

Indexed keywords

ANALGESIC AGENT; ANTIARRHYTHMIC AGENT; ANTICONVULSIVE AGENT; CANNABINOID; CARBAMAZEPINE; CYTOCHROME P450 2D6; DEXTROMETHORPHAN; DRONABINOL; DULOXETINE; GABAPENTIN; HARKOSERIDE; KETAMINE; LAMOTRIGINE; MEMANTINE; MORPHINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NARCOTIC ANALGESIC AGENT; NORADRENALIN UPTAKE INHIBITOR; OXYCODONE; PLACEBO; PREGABALIN; QUINIDINE; RETIGABINE; SEROTONIN UPTAKE INHIBITOR; SODIUM CHANNEL; SODIUM CHANNEL BLOCKING AGENT; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

ACTION POTENTIAL; ANALGESIA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DIZZINESS; DROWSINESS; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESPONSE; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FATIGUE; GASTROINTESTINAL DISEASE; GENETIC POLYMORPHISM; HUMAN; INJECTION SITE REACTION; MENTAL DISEASE; NAUSEA; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NEUROPATHIC PAIN; NEUROTRANSMISSION; NOCICEPTIVE RECEPTOR; NONHUMAN; ORTHOSTATIC HYPOTENSION; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; PHENOTYPE; PRACTICE GUIDELINE; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; SOMNOLENCE; XEROSTOMIA;

EID: 55649113716     PISSN: 17512433     EISSN: None     Source Type: Journal    
DOI: 10.1586/17512433.1.5.683     Document Type: Review

References (76)

1. Cruccu G. Treatment of painful neuropathy. Curr. Opin. Neurol. 20, 531-535 (2007).
2. Butera JA. Miniperspectives: recent approaches in the treatment of neuropathic pain. J. Med. Chem. 50, 2543-2546 (2007).
3. Hall GC, Carroll D, Parry D, McQuay H. Epidemiology and treatment of neuropathic pain: The UK primary care perspective. Pain 122, 156-162 (2006).
4. Bouhassira D, Attal N, Alchaar H et al. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain 114, 29-36 (2005).
5. Rowbotham MC. Mechanisms of neuropathic pain and their implications for the design of clinical trials. Neurology 65, S66-S73 (2005).
6. Piguet V, Cedraschi C, Dumont P et al. Patients' representations of antidepressants: a clue to nonadherence? Clin. J. Pain 23, 669-675 (2007).
7. Finnerup NB, Sindrup SH, Jensen TS. Chronic neuropathic pain: mechanisms, drug targets and measurement. Fundam. Clin. Pharmacol. 21, 129-136 (2007).
8. Cummins TR, Sheets PL, Waxmann SG. The roles of sodium channels in nociception: implications for mechanisms of pain. Pain 131, 243-257 (2007).
9. Wiffen PJ, McQuay HJ, Moore RA. Carbamazepine for acute and chronic pain. Cochrane Database Syst. Rev. 3, CD005451 (2005).
10. Khaliq W, Alam S, Puri N. Topical lidocaine for the treatment of postherpetic neuralgia. Cochrane Database Syst. Rev. 2, CD004846 (2007).
11. Sheets PL, Heers C, Stoehr T, Cummins TR. Differential block of sensory neuronal voltage-gated sodium channels by lacosamide [(2R)-2-(acetylamino)-N- benzyl-3-methoxypropanamide], lidocaine, and carbamazepine. J. Pharmacol. Exp. Ther. 326, 89-99 (2008).
12. Errington AC, Stöhr T, Heers C, Lees G. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol. Pharmacol. 73, 157-169 (2008).
13. Doty P, Rudd DG, Stoehr T, Thomas D. Lacosamide. Neurotherapeutics 4, 145-148 (2007).
14. Bodenschatz R, Bretschneider M, Thierfelder S, Bongardt S. A multi-center open-label, follow-on trial to assess the long-term safety and efficacy of lacosamide in subjects with painful diabetic neuropathy. Eur. J. Pain 11(Suppl. 1), S77 (2007).
15. Roza C, Lopez-Garcia JA. Retigabine, the specific KCNQ channel opener, blocks ectopic discharges in axotomized sensory fibres. Pain (2008) (Epub ahead of print).
16. +-ketamine in refractory CRPS patients. Pain Med. 9, 44-54 (2008).
17. Cvrcek P. Side Effects of ketamine in the long-term treatment of neuropathic pain. Pain Med. 9, 253-257 (2008).
18. AVANIR Pharmaceuticals. Efficacy and safety of dextromethorphan/ quinidine in treating painful diabetic peripheral neuropathy: results of Phase III, double blind, randomized, placebo-controlled trial. Presented at: 2nd International Congress On Neuropathic Pain. Berlin, Germany, 7-10 June 2007.
19. AVANIR Pharmaceuticals. Improved patient-centered outcomes with dextromethorphan/quinidine vs placebo in a Phase III, double-blind, randomized, placebo-controlled trial investigating painful diabetic peripheral neuropathy. Presented at: 2nd International Congress On Neuropathic Pain. Berlin, Germany, 7-10 June 2007.
20. Zhu CZ, Baker S, Ei-Kouhen O et al. Analgesic activity of metabotropic glutamate receptor 1 antagonists on spontaneous post-operative pain in rats. Eur. J. Pharmacol. 12, 314-321 (2008).
21. A receptor subtypes. Nature 451, 330-335 (2008).
22. Ji RR, Kawasaki Y, Zhuang ZY, Wen YR, Decosterd I. Possible role of spinal astrocytes in maintaining chronic pain sensitization: review of current evidence with focus on βFGF/JNK pathway. Neuron Glia Biol. 2, 259-269 (2006).
23. Scholz J, Woolf CJ. The neuropathic pain triad: neurons, immune cells and glia. Nature Neurosci. 10, 1361-1368 (2007).
24. Jensen TR, Baron R. Translation of symptoms and signs into mechanisms in neuropathic pain. Pain 102, 1-8 (2003).
25. Finnerup NB, Jensen TS. Mechanism of disease: mechanism-based classification of neuropathic pain a critical analysis. Nature Clin. Pract. Neurol. 2, 107-115 (2006).
26. Besson M, Brook P, Chizh BA, Pickering AE. Tactile allodynia in patients with postherpetic neuralgia: lack of change in skin blood flow upon dynamic stimulation. Pain 117, 157-161 (2005).
27. Samer CF, Piguet V, Dayer P, Desmeules J. Genetic polymorphism and drug interactions: their importance in the treatment of pain. Can. J. Anaesth. 52, 806-821 (2005).
28. Gasche Y, Daali Y, Fathi M et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N. Engl. J. Med. 351, 2827-2831 (2004).
29. Sindrup SH, Madsen C, Brosen K. The effect of tramadol in painful polyneuropathy in relation to serum drug and metabolite levels. Clin. Pharmacol. Ther. 66, 636-641 (1999).
30. Rau T, Wohlleben G, Wuttke H et al. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants - a pilot study. Clin. Pharmacol. Ther. 75, 386-393 (2004).
31. Attal N, Cruccu G, Haanpää M et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur. J. Neurol. 13, 1153-1169 (2006).
32. Dworkin RH, O'Connor AB, Backonja M et al. Pharmacological management of neuropathic pain: evidence-based recommendations. Pain 132, 237-251 (2007).
33. Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 118, 289-305 (2005).
34. Finnerup NB, Otto M, Jensen TS, Sindrup SH. An evidence-based algorithm for the treatment of neuropathic pain. Med. Gen. Med. 15, 36 (2007).
35. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst. Rev. 4, CD005454 (2007).
36. Raskin J, Pritchett YL, Wang F et al. Double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med. 6, 346-356 (2005).
37. Goldsteina DJ, Lub Y, Detke MJ et al. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 116, 109-118 (2005).
38. Wernicke JF, Pritchett YL, D'Souza ND et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 67, 1411-1420 (2006).
39. Wernicke JF, Wang F, Pritchett YL et al. An open-label 52-week clinical extension comparing duloxetine with routine care in patients with diabetic peripheral neuropathic pain. Pain Med. 8, 503-512 (2007).
40. Kajdasz DK, Iyengar S, Desaiah D et al. Duloxetine for the management of diabetic peripheral neuropathic pain: evidence-based findings from post hoc analysis of three multicenter, randomized, double-blind, placebo-controlled, parallel-group studies. CLin. Ther. 29, 2536-2546 (2007).
41. Wiffen P, Collins S, McQuay H, Carroll D, Jadad A, Moore A. Anticonvulsant drugs for acute and chronic pain. Cochrane Database Syst. Rev. 2, CD006044 (2005).
42. Wiffen PJ, McQuay HJ, Edwards JE, Moore RA. Gabapentin for acute and chronic pain. Cochrane Database Syst. Rev. 3, CD005452 (2005).
43. Freynhagena R, Strojekb K, Griesing T et al. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain 115, 254-263 (2005).
44. Van Seventer R, Feistrer HA, Jung JP Jr et al. Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial. Curr. Med. Res. Opin. 22, 375-384 (2006).
45. Tölle T, Freynhagen R, Versavel M et al. Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study. Eur. J. Pain 12, 203-213 (2008).
46. Gidal BE, Radulovic LL, Kruger S et al. Inter- and intra-subject variability in gabapentin absorption and absolute bioavailability. Epilepsy Res. 40, 123-127 (2000).
47. Van Seventer R, Feistrer HA, Jung JP Jr et al. Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial. Curr. Med. Res. Opin. 22, 375-384 (2006).
48. Siddall PJ, Cousins MJ, Otte A et al. Pregabalin in central neuropathic pain associated with spinal cord injury. Neurology 67, 1792-1800 (2006).
49. Wiffen PJ, Rees J. Lamotrigine for acute and chronic pain. Cochrane Database Syst. Rev. 2, CD006044 (2007).
50. Thienel U, Neto W, Schwabe SK et al. Topiramate Diabetic Neuropathic Pain Study Group. Topiramate in painful polyneuropathy: findings from three double-blinded placebo-controlled trials. Acta Neurol. Scand. 110, 221-231 (2004).
51. Raskin P, Donofrio PD, Rosenthal NR et al. Topiramate vs placebo in painful diabetic polyneuropathy: analgesic and metabolic effects. Neurology 63, 865-873 (2004).
52. Ma QP, Tian L, Woolf CJ. Resection of sciatic nerve re-triggers central sprouting of A-fibre primary afferents in the rat. Neurosci. Lett. 288, 215-218 (2000),
53. 11C] diprenorphine binding and PET. Eur. J. Pain 8(5), 479-485 (2004).
54. Heinricher MM, Neubert MJ. Neural basis for the hyperalgesic action of cholecystokinin in the rostral ventromedial medulla. J. Neurophysiol. 92, 1982-1989 (2004).
55. Benedetti F, Vighetti S, Amanzion M et al. Dose-response relationship of opioids in nocicpetive and neuropathic postoperative pain. Pain 74, 205-211 (1998).
56. Eisenberg E, McNicol E, Carr DB. Opioids for neuropathic pain. Cochrane Database Syst. Rev. 3, CD006146 (2006).
57. Rowbotham MC, Twilling L, Davies PS et al. Oral opioid therapy for chronic peripheral and central neuropathic pain. N. Engl. J. Med. 348, 1223-1232 (2008).
58. Eisenberg E, McNicol E, Carr DB. Efficacy and safety of opioid agonists in the treatment of neuropathic pain of non malignant origin systematic review and meta-analysis of randomized controlled trials. JAMA 293, 3043-3051 (2005).
59. Hollingshead J, Dühmke RM, Cornblath DR. Tramadol for neuropathic pain. Cochrane Database Syst. Rev. 3, CD003726 (2006).
60. Gimbel JS, Richards P, Portenoy RK. Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology 60, 927-934 (2003)
61. Watson CPN, Moulinb D, Watt-Watson J et al. Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain 105, 71-78 (2003).
62. Eija K. How different is oxycodone from morphine? Pain 132, 227-228 (2007).
63. Riley J, Eisenberg E, Müller Schwefe G et al. Oxycodone: a review of its use in the management of pain. Curr. Med. Res. Opin. 24, 175-192 (2008).
64. Morley JS, Britson J, Nash TP et al. Low-dose methadone has an analgesic effect in neuropathic pain: a double-blind randomized controlled crossover trial. Palliative Med. 17, 576-587 (2003).
65. Moulin DE, Clark AJ, Gilron I. Pharmacological management of chronic neuropathic pain - consensus statement and guidelines from the Canadian Pain Society. Pain Res. Manag. 12, 13-21 (2007).
66. Terpening CM, Johnson WM. Methadone as an analgesic: a review of the risks and benefits. W. V. Med. J. 103, 14-18 (2007).
67. Ehret GB, Voide C, Gex-Fabry M et al. Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors. Arch. Intern. Med. 166(12), 1280-1287 (2006).
68. Campbell FA, Tramer MR, Carroll D et al. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 323, 13-16 (2001).
69. Rog DJ, Nurmikko TJ, Friede T. Randomized, controlled trial of cannabis based medicine in central pain in multiple sclerosis. Neurology 65, 812-819 (2005).
70. Nurmikko TJ, Serpell MG, Hoggart B et al. Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain 133, 210-220 (2007).
71. Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 329, 253-261 (2004).
72. Rog DJ, Nurmikko TJ, Young CA. Oromucosal A9-tetrahydrocannabinol/ cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. Clin. Ther. 29, 2068-2079 (2007).
73. Frank B, Serpell MG, Hughes J, Matthews JNS, Kapur D. Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. BMJ 336, 199-201 (2008).
74. Gilron I, Bailey JM, Tu D et al. Morphine, gabapentin, or their combination for neuropathic pain. N. Engl. J. Med. 352, 1324-1334 (2005).
75. Eckhardt K, Ammon S, Hofmann U et al. Gabapentin enhances the analgesic effect of morphine in healthy volunteers. Anesth. Analg. 91, 185-191 (2000).
76. Hanna M, O'Brien C, Wilson MC. Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients. Eur. J. Pain 6, 804-813 (2008).